Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL033
MIFTS: 26

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Childhood Malignant Schwannoma

About this section

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 71
Pediatric Mpnst 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:7732
NCIt 49 C8094
UMLS 71 C0279987
Sources

Summaries for Childhood Malignant Schwannoma

About this section
MalaCards based summary : Childhood Malignant Schwannoma, also known as childhood neurofibrosarcoma, is related to osteofibrous dysplasia and cystadenocarcinoma. An important gene associated with Childhood Malignant Schwannoma is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Glioblastoma Multiforme. The drugs Mechlorethamine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and skin.

Sources

Related Diseases for Childhood Malignant Schwannoma

About this section

Diseases related to Childhood Malignant Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 osteofibrous dysplasia 10.1 SPP1 NF1
2 cystadenocarcinoma 9.9 SPP1 BIRC5
3 malignant pleural mesothelioma 9.9 SPP1 BIRC5
4 basal cell nevus syndrome 9.8 NF1 CCND1
5 atypical teratoid rhabdoid tumor 9.7 SPP1 CCND1
6 keratocystic odontogenic tumor 9.7 CCND1 BIRC5
7 adult malignant schwannoma 9.7 SPP1 NF1 BIRC5
8 von hippel-lindau syndrome 9.7 NF1 CCND1
9 skin squamous cell carcinoma 9.7 CCND1 BIRC5
10 inflammatory myofibroblastic tumor 9.7 CCND1 BIRC5
11 leiomyosarcoma 9.6 NF1 CCND1
12 malignant peripheral nerve sheath tumor 9.5 NF1 CCND1
13 gastrointestinal stromal tumor 9.4 SPP1 NF1 CCND1
14 leukemia, chronic myeloid 9.4 NF1 CCND1 BIRC5
15 peripheral nervous system neoplasm 9.3 NF1 CCND1
16 pancreatic adenocarcinoma 9.3 SPP1 CCND1 BIRC5
17 gastric adenocarcinoma 9.3 SPP1 CCND1 BIRC5
18 squamous cell carcinoma, head and neck 9.2 SPP1 CCND1 BIRC5
19 glioblastoma multiforme 9.2 NF1 CCND1 BIRC5
20 lung cancer susceptibility 3 9.1 SPP1 NF1 CCND1 BIRC5

Graphical network of the top 20 diseases related to Childhood Malignant Schwannoma:



Diseases related to Childhood Malignant Schwannoma
Sources

Symptoms & Phenotypes for Childhood Malignant Schwannoma

About this section
Sources

Drugs & Therapeutics for Childhood Malignant Schwannoma

About this section

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Ifosfamide Approved Phase 3 3778-73-2 3690
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Liposomal doxorubicin Phase 3 31703
13 Alkylating Agents Phase 3
14 Antirheumatic Agents Phase 3
15 Anti-Bacterial Agents Phase 3
16 Antibiotics, Antitubercular Phase 3
17
Isophosphamide mustard Phase 3 0
18 Topoisomerase Inhibitors Phase 3
19 Immunologic Factors Phase 3
20 Etoposide phosphate Phase 3
21 Anti-Infective Agents Phase 3
22 Immunosuppressive Agents Phase 3
23 Antimitotic Agents Phase 3
24 Gastrointestinal Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Dermatologic Agents Phase 3
27 Antipruritics Phase 3
28 Histamine H1 Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Histamine Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Serotonin Antagonists Phase 3
33 Anti-Allergic Agents Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Lenograstim Approved, Investigational Phase 2 135968-09-1
36 Protein Kinase Inhibitors Phase 2
37 Imatinib Mesylate Phase 2 220127-57-1 123596
38 Adjuvants, Immunologic Phase 2
39
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
40 Anti-Inflammatory Agents Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 1
42 Analgesics, Non-Narcotic Phase 1
43 Cyclooxygenase 2 Inhibitors Phase 1
44 Cyclooxygenase Inhibitors Phase 1
45 Analgesics Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
6 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
7 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Sources

Genetic Tests for Childhood Malignant Schwannoma

About this section
Sources

Anatomical Context for Childhood Malignant Schwannoma

About this section

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

40
Bone, Lung, Skin, Myeloid
Sources

Publications for Childhood Malignant Schwannoma

About this section

Articles related to Childhood Malignant Schwannoma:

# Title Authors PMID Year
1
Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. 61
31889416 2019
2
Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. 61
31241238 2019
3
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. 61
30883338 2019
4
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). 61
24303016 2013
Sources

Variations for Childhood Malignant Schwannoma

About this section
Sources

Expression for Childhood Malignant Schwannoma

About this section
Search GEO for disease gene expression data for Childhood Malignant Schwannoma.
Sources

Pathways for Childhood Malignant Schwannoma

About this section

Pathways related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Interleukin-4 and 13 signaling 65
11.49 CCND1 BIRC5
2
Glioblastoma Multiforme 63
11.45 NF1 CCND1
3
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.27 KCNIP4 CCND1
4
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.12 CCND1 BIRC5
5
ATF-2 transcription factor network 1
11 NF1 CCND1
6
Hepatitis C and Hepatocellular Carcinoma 1
10.86 CCND1 BIRC5
7
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
10.55 SPP1 CCND1
8
FOXM1 transcription factor network 1
10.19 CCND1 BIRC5
Sources

GO Terms for Childhood Malignant Schwannoma

About this section

Biological processes related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 osteoblast differentiation GO:0001649 9.26 SPP1 NF1
2 response to organic substance GO:0010033 9.16 SPP1 CCND1
3 liver development GO:0001889 8.96 NF1 CCND1
4 response to steroid hormone GO:0048545 8.62 SPP1 CCND1
Sources

Sources for Childhood Malignant Schwannoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....